{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:43:50Z","timestamp":1785152630692,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04587-7","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:45:35Z","timestamp":1773107135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and\/or obesity in patients with Cushing\u2019s syndrome: a multicenter retrospective study"],"prefix":"10.1007","volume":"91","author":[{"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema L","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Hanzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fania R. O. L.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Manzano Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Castro Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Albacete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"Suppl 1","key":"4587_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","volume":"92","author":"G Arnaldi","year":"2010","unstructured":"G. Arnaldi, V.M. Scandali, L. Trementino, M. Cardinaletti, G. Appolloni, M. Boscaro, Pathophysiology of dyslipidemia in cushing\u2019s syndrome. Neuroendocrinology. 92(Suppl 1), 86\u201390 (2010)","journal-title":"Neuroendocrinology"},{"issue":"Suppl 1","key":"4587_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000314272","volume":"92","author":"P Chanson","year":"2010","unstructured":"P. Chanson, S. Salenave, Metabolic syndrome in cushing\u2019s syndrome. Neuroendocrinology. 92(Suppl 1), 96\u2013101 (2010)","journal-title":"Neuroendocrinology"},{"issue":"4","key":"4587_CR3","doi-asserted-by":"publisher","first-page":"M133","DOI":"10.1530\/EJE-15-0354","volume":"173","author":"F Ferra\u00f9","year":"2015","unstructured":"F. Ferra\u00f9, M. Korbonits, Metabolic comorbidities in cushing\u2019s syndrome. Eur. J. Endocrinol. 173(4), M133\u2013157 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"4587_CR4","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1210\/jc.2008-1297","volume":"93","author":"B Kola","year":"2008","unstructured":"B. Kola, M. Christ-Crain, F. Lolli, G. Arnaldi, G. Giacchetti, M. Boscaro et al., Changes in adenosine 5\u2019-monophosphate-activated protein kinase as a mechanism of visceral obesity in cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 93(12), 4969\u20134973 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 1","key":"4587_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000314319","volume":"92","author":"R Pivonello","year":"2010","unstructured":"R. Pivonello, De M. Leo, P. Vitale, A. Cozzolino, C. Simeoli, De M.C. Martino et al., Pathophysiology of diabetes mellitus in cushing\u2019s syndrome. Neuroendocrinology. 92(Suppl 1), 77\u201381 (2010)","journal-title":"Neuroendocrinology"},{"issue":"8","key":"4587_CR6","doi-asserted-by":"publisher","first-page":"e13143","DOI":"10.1111\/jne.13143","volume":"34","author":"R Salehidoost","year":"2022","unstructured":"R. Salehidoost, M. Korbonits, Glucose and lipid metabolism abnormalities in cushing\u2019s syndrome. J. Neuroendocrinol. 34(8), e13143 (2022)","journal-title":"J. Neuroendocrinol."},{"key":"4587_CR7","doi-asserted-by":"crossref","unstructured":"A. Sharma, A. Vella, Glucose metabolism in cushing\u2019s syndrome. Curr. Opin. Endocrinol. Diabetes Obes. 27(3), 140\u2013145 (2020)","DOI":"10.1097\/MED.0000000000000537"},{"key":"4587_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fendo.2019.00321","volume":"10","author":"M Barbot","year":"2019","unstructured":"M. Barbot, F. Ceccato, C. Scaroni, The pathophysiology and treatment of hypertension in patients with cushing\u2019s syndrome. Front. Endocrinol. (Lausanne). 10, 321 (2019)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"Suppl 1","key":"4587_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000314315","volume":"92","author":"MV Cicala","year":"2010","unstructured":"M.V. Cicala, F. Mantero, Hypertension in cushing\u2019s syndrome: from pathogenesis to treatment. Neuroendocrinology. 92(Suppl 1), 44\u201349 (2010)","journal-title":"Neuroendocrinology"},{"issue":"5","key":"4587_CR10","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"R.M. Carey, D.A. Calhoun, G.L. Bakris, R.D. Brook, S.L. Daugherty, C.R. Dennison-Himmelfarb et al., Resistant hypertension: Detection, Evaluation, and management: A scientific statement from the American heart association. Hypertension. 72(5), e53\u201390 (2018)","journal-title":"Hypertension"},{"issue":"11","key":"4587_CR11","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1161\/HYPERTENSIONAHA.123.21185","volume":"80","author":"U Stifel","year":"2023","unstructured":"U. Stifel, F. Vogel, G. Caratti, M. Reincke, J. Tuckermann, Unique gene expression signature in periadrenal adipose tissue identifies a high blood pressure group in patients with Cushing syndrome. Hypertension. 80(11), 2333\u20132344 (2023)","journal-title":"Hypertension"},{"key":"4587_CR12","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"H. Yao, A. Zhang, D. Li, Y. Wu, C.Z. Wang, J.Y. Wan et al., Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 384, e076410 (2024)","journal-title":"BMJ"},{"issue":"4","key":"4587_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Z.Z. Htike, F. Zaccardi, D. Papamargaritis, D.R. Webb, K. Khunti, M.J. Davies, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes. Metab. 19(4), 524\u2013536 (2017)","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"4587_CR14","first-page":"501562","volume":"72","author":"F Garagoli","year":"2025","unstructured":"F. Garagoli, W. Masson, L. Barbagelata, M. Lobo, Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Endocrinol. Diabetes Nutr. (Engl Ed). 72(5), 501562 (2025)","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"issue":"2","key":"4587_CR15","first-page":"101538","volume":"72","author":"MA Rubio-Herrera","year":"2025","unstructured":"M.A. Rubio-Herrera, I. Bret\u00f3n Lesmes, Controversies on the effects of GLP-1 receptor agonist treatment on gastric emptying. Endocrinol. Diabetes Nutr. (Engl Ed). 72(2), 101538 (2025)","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"issue":"7","key":"4587_CR16","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","volume":"140","author":"SM Dunlay","year":"2019","unstructured":"S.M. Dunlay, M.M. Givertz, D. Aguilar, L.A. Allen, M. Chan, A.S. Desai et al., Type 2 diabetes mellitus and heart failure: A scientific statement from the American heart association and the heart failure society of america: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 140(7), e294\u2013324 (2019)","journal-title":"Circulation"},{"issue":"2","key":"4587_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.13888","volume":"22","author":"E Mannucci","year":"2020","unstructured":"E. Mannucci, I. Dicembrini, B. Nreu, M. Monami, Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: an updated meta-analysis and subgroup analysis of randomized controlled trials. Diabetes Obes. Metab. 22(2), 203\u2013211 (2020)","journal-title":"Diabetes Obes. Metab."},{"issue":"35","key":"4587_CR18","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","volume":"41","author":"F. Marsico","year":"2020","unstructured":"F. Marsico, S. Paolillo, P. Gargiulo, D. Bruzzese, S. Dell\u2019Aversana, I. Esposito et al., Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur. Heart J. 41(35), 3346\u20133358 (2020)","journal-title":"Eur. Heart J."},{"issue":"7","key":"4587_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"J.R. Ussher","year":"2023","unstructured":"J.R. Ussher, D.J. Drucker, Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20(7), 463\u2013474 (2023)","journal-title":"Nat. Rev. Cardiol."},{"issue":"10","key":"4587_CR20","first-page":"447","volume":"71","author":"S Guti\u00e9rrez Medina","year":"2024","unstructured":"S. Guti\u00e9rrez Medina, E. S\u00e1nchez Campayo, S. Guadalix, J. Escalada, Super response to liraglutide in people with obesity: A case report and literature review. Endocrinol. Diabetes Nutr. (Engl Ed). 71(10), 447\u2013453 (2024)","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"issue":"9","key":"4587_CR21","first-page":"405","volume":"71","author":"V Perez de Arenaza Pozo","year":"2024","unstructured":"V. Perez de Arenaza Pozo, J. C\u00e1rdenas Salas, C. V\u00e1zquez Mart\u00ednez, Potential of insulin deprescription adding a GLP-1 receptor agonist as a therapeutic strategy to improve the metabolic profiles of patients with type 2 diabetes mellitus. Endocrinol. Diabetes Nutr. (Engl Ed). 71(9), 405\u2013407 (2024)","journal-title":"Endocrinol. Diabetes Nutr. (Engl Ed)"},{"key":"4587_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000486002","volume":"49","author":"F Ferra\u00f9","year":"2018","unstructured":"F. Ferra\u00f9, M. Korbonits, Metabolic syndrome in cushing\u2019s syndrome patients. Front. Horm. Res. 49, 85\u2013103 (2018)","journal-title":"Front. Horm. Res."},{"issue":"1","key":"4587_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","volume":"64","author":"MH Schernthaner-Reiter","year":"2019","unstructured":"M.H. Schernthaner-Reiter, C. Siess, A. Gessl, C. Scheuba, S. Wolfsberger, P. Riss et al., Factors predicting long-term comorbidities in patients with cushing\u2019s syndrome in remission. Endocrine. 64(1), 157\u2013168 (2019)","journal-title":"Endocrine"},{"key":"4587_CR24","doi-asserted-by":"publisher","first-page":"112382","DOI":"10.1016\/j.diabres.2025.112382","volume":"226","author":"Q Cui","year":"2025","unstructured":"Q. Cui, Y. Li, X. Liu, Q. Sun, W. Sun, M. He et al., The outcome of abnormal glucose metabolism and its clinical features in patients with cushing\u2019s disease after curative surgery. Diabetes Res. Clin. Pract. 226, 112382 (2025)","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"11","key":"4587_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, Van L.F. Gaal, I. Lingvay et al., Once-Weekly semaglutide in adults with overweight or obesity. N Engl. J. Med. 384(11), 989\u20131002 (2021)","journal-title":"N Engl. J. Med."},{"issue":"14","key":"4587_CR26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"D. Rubino, N. Abrahamsson, M. Davies, D. Hesse, F.L. Greenway, C. Jensen et al., Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14), 1414\u20131425 (2021)","journal-title":"JAMA"},{"issue":"3","key":"4587_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"A.M. Jastreboff","year":"2022","unstructured":"A.M. Jastreboff, L.J. Aronne, N.N. Ahmad, S. Wharton, L. Connery, B. Alves et al., Tirzepatide Once Weekly for the Treatment of Obesity. N Engl. J. Med. 387(3), 205\u2013216 (2022)","journal-title":"N Engl. J. Med."},{"issue":"9","key":"4587_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"J.P. Fr\u00edas","year":"2021","unstructured":"J.P. Fr\u00edas, P. Auerbach, H.S. Bajaj, Y. Fukushima, I. Lingvay, S. Macura et al., Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 9(9), 563\u2013574 (2021)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"4587_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"D. Dahl, Y. Onishi, P. Norwood, R. Huh, R. Bray, H. Patel et al., Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6), 534\u2013545 (2022)","journal-title":"JAMA"},{"issue":"8","key":"4587_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"B. Wang, J. Zhong, H. Lin, Z. Zhao, Z. Yan, H. He et al., Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15(8), 737\u2013749 (2013)","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"4587_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","volume":"37","author":"F Sun","year":"2015","unstructured":"F. Sun, S. Wu, J. Wang, S. Guo, S. Chai, Z. Yang et al., Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin. Ther. 37(1), 225\u2013241e8 (2015)","journal-title":"Clin. Ther."},{"issue":"10019","key":"4587_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"M.J. Armstrong, P. Gaunt, G.P. Aithal, D. Barton, D. Hull, R. Parker et al., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 387(10019), 679\u2013690 (2016)","journal-title":"Lancet"},{"issue":"12","key":"4587_CR33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"P.N. Newsome, K. Buchholtz, K. Cusi, M. Linder, T. Okanoue, V. Ratziu et al., A Placebo-Controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl. J. Med. 384(12), 1113\u20131124 (2021)","journal-title":"N Engl. J. Med."},{"issue":"6","key":"4587_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R. Loomba","year":"2023","unstructured":"R. Loomba, M.F. Abdelmalek, M.J. Armstrong, M. Jara, M.S. Kj\u00e6r, N. Krarup et al., Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8(6), 511\u2013522 (2023)","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"4587_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1210\/jc.2018-01420","volume":"104","author":"B Winzeler","year":"2019","unstructured":"B. Winzeler, da I. Concei\u00e7\u00e3o, J. Refardt, C.O. Sailer, G. Dutilh, M. Christ-Crain, Effects of Glucagon-Like Peptide-1 receptor agonists on Hypothalamic-Pituitary-Adrenal axis in healthy volunteers. J. Clin. Endocrinol. Metab. 104(1), 202\u2013208 (2019)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4587_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1055\/s-2007-955096","volume":"115","author":"RA Ritzel","year":"2007","unstructured":"R.A. Ritzel, N. Kleine, J.J. Holst, B. Willms, W. Schmiegel, M.A. Nauck, Preserved GLP-1 effects in a diabetic patient with cushing\u2019s disease. Exp. Clin. Endocrinol. Diabetes. 115(2), 146\u2013150 (2007)","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"2","key":"4587_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"A. Colao, De C. Block, M.S. Gaztambide, S. Kumar, J. Seufert, F.F. Casanueva, Managing hyperglycemia in patients with cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary. 17(2), 180\u2013186 (2014)","journal-title":"Pituitary"},{"key":"4587_CR38","doi-asserted-by":"publisher","first-page":"1248985","DOI":"10.3389\/fendo.2023.1248985","volume":"14","author":"V Guarnotta","year":"2023","unstructured":"V. Guarnotta, F. Emanuele, R. Salzillo, M. Bonsangue, C. Amato, M.I. Mineo et al., Practical therapeutic approach in the management of diabetes mellitus secondary to cushing\u2019s syndrome, acromegaly and neuroendocrine tumours. Front. Endocrinol. (Lausanne). 14, 1248985 (2023)","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04587-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04587-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:05:31Z","timestamp":1773785131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04587-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4587"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04587-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"108"}}